

# Giuseppe Toffoli

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/4944361/giuseppe-toffoli-publications-by-year.pdf>

**Version:** 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

283  
papers

6,653  
citations

41  
h-index

66  
g-index

323  
ext. papers

7,907  
ext. citations

4.8  
avg. IF

5.85  
L-index

#	Paper	IF	Citations
283	Cisplatin resistance can be curtailed by blunting Bnip3-mediated mitochondrial autophagy.. <i>Cell Death and Disease</i> , <b>2022</b> , 13, 398	9.8	4
282	A rapid, simple and sensitive LC-MS/MS method for lenvatinib quantification in human plasma for therapeutic drug monitoring. <i>PLoS ONE</i> , <b>2021</b> , 16, e0259137	3.7	0
281	Integration of DNA sequencing with population pharmacokinetics to improve the prediction of irinotecan exposure in cancer patients. <i>British Journal of Cancer</i> , <b>2021</b> ,	8.7	2
280	A new dried blood spot LC-MS/MS method for therapeutic drug monitoring of palbociclib, ribociclib, and letrozole in patients with cancer. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , <b>2021</b> , 1185, 122985	3.2	2
279	Pharmacological strategies to prevent SARS-CoV-2 infection and treat the early phases of COVID-19. <i>International Journal of Infectious Diseases</i> , <b>2021</b> , 104, 441-451	10.5	10
278	A New Epigenetic Model to Stratify Glioma Patients According to Their Immunosuppressive State. <i>Cells</i> , <b>2021</b> , 10,	7.9	2
277	Dried Blood Spot Technique Applied in Therapeutic Drug Monitoring of Anticancer Drugs: a Review on Conversion Methods to Correlate Plasma and Dried Blood Spot Concentrations. <i>Pharmaceutical Research</i> , <b>2021</b> , 38, 759-778	4.5	7
276	Refining neutropenia risk assessment in patients treated with first-line endocrine therapy (ET) and cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) for metastatic breast cancer (MBC) through a cell-free DNA workflow (cfDNA).. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 1027-1027	2.2	0
275	Sex Disparities in Efficacy in COVID-19 Vaccines: A Systematic Review and Meta-Analysis. <i>Vaccines</i> , <b>2021</b> , 9,	5.3	17
274	Prognostic role of visceral fat for overall survival in metastatic colorectal cancer: A pilot study. <i>Clinical Nutrition</i> , <b>2021</b> , 40, 286-294	5.9	8
273	An SPR investigation into the therapeutic drug monitoring of the anticancer drug imatinib with selective aptamers operating in human plasma. <i>Analyst, The</i> , <b>2021</b> , 146, 1714-1724	5	5
272	The Efficacy of Anti-PD-L1 Treatment in Melanoma Is Associated with the Expression of the ECM Molecule EMILIN2. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	1
271	Nanoparticles-Based Oligonucleotides Delivery in Cancer: Role of Zebrafish as Animal Model. <i>Pharmaceutics</i> , <b>2021</b> , 13,	6.4	3
270	Characterization of Thermo-responsive Poly-N-Vinylcaprolactam Polymers for Biological Applications. <i>Polymers</i> , <b>2021</b> , 13,	4.5	4
269	Role of Virus-Related Chronic Inflammation and Mechanisms of Cancer Immune-Suppression in Pathogenesis and Progression of Hepatocellular Carcinoma. <i>Cancers</i> , <b>2021</b> , 13,	6.6	4
268	Development and validation of a selective SPR aptasensor for the detection of anticancer drug irinotecan in human plasma samples. <i>Analytical and Bioanalytical Chemistry</i> , <b>2021</b> , 413, 1225-1236	4.4	3
267	A Novel Epigenetic Machine Learning Model to Define Risk of Progression for Hepatocellular Carcinoma Patients. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	2

266	SMAD3 Host and Tumor Profiling to Identify Locally Advanced Rectal Cancer Patients at High Risk of Poor Response to Neoadjuvant Chemoradiotherapy.. <i>Frontiers in Pharmacology</i> , <b>2021</b> , 12, 778781	5.6	1
265	Genetic Variants of the Gene, Telomere Length, and Circulating as Prognostic Markers in Rectal Cancer Patients. <i>Cancers</i> , <b>2020</b> , 12,	6.6	2
264	New insights into the pharmacological, immunological, and CAR-T-cell approaches in the treatment of hepatocellular carcinoma. <i>Drug Resistance Updates</i> , <b>2020</b> , 51, 100702	23.2	32
263	Soluble HLA-G expression levels and HLA-G/irinotecan association in metastatic colorectal cancer treated with irinotecan-based strategy. <i>Scientific Reports</i> , <b>2020</b> , 10, 8773	4.9	3
262	Adipose mesenchymal stromal/stem cells expanded by a GMP compatible protocol displayed improved adhesion on cancer cells in flow conditions. <i>Annals of Translational Medicine</i> , <b>2020</b> , 8, 533	3.2	3
261	Immunogenetic markers in IL17F predict the risk of metastases spread and overall survival in rectal cancer patients treated with neoadjuvant chemoradiotherapy. <i>Radiotherapy and Oncology</i> , <b>2020</b> , 149, 30-37	5.3	4
260	A LC-MS/MS method for therapeutic drug monitoring of sorafenib, regorafenib and their active metabolites in patients with hepatocellular carcinoma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , <b>2020</b> , 187, 113358	3.5	8
259	The Dual Role of the Liver in Nanomedicine as an Actor in the Elimination of Nanostructures or a Therapeutic Target. <i>Journal of Oncology</i> , <b>2020</b> , 2020, 4638192	4.5	16
258	Optimal Sampling Strategies for Irinotecan (CPT-11) and its Active Metabolite (SN-38) in Cancer Patients. <i>AAPS Journal</i> , <b>2020</b> , 22, 59	3.7	0
257	Clonal Selection of a Novel Deleterious TP53 Somatic Mutation Discovered in ctDNA of a KIT/PDGFRA Wild-Type Gastrointestinal Stromal Tumor Resistant to Imatinib. <i>Frontiers in Pharmacology</i> , <b>2020</b> , 11, 36	5.6	5
256	Germline and Somatic Pharmacogenomics to Refine Rectal Cancer Patients Selection for Neo-Adjuvant Chemoradiotherapy. <i>Frontiers in Pharmacology</i> , <b>2020</b> , 11, 897	5.6	3
255	Glucose Metabolism and Oxidative Stress in Hepatocellular Carcinoma: Role and Possible Implications in Novel Therapeutic Strategies. <i>Cancers</i> , <b>2020</b> , 12,	6.6	24
254	Simultaneous quantification of palbociclib, ribociclib and letrozole in human plasma by a new LC-MS/MS method for clinical application. <i>PLoS ONE</i> , <b>2020</b> , 15, e0228822	3.7	11
253	ELISA assay employing epitope-specific monoclonal antibodies to quantify circulating HER2 with potential application in monitoring cancer patients undergoing therapy with trastuzumab. <i>Scientific Reports</i> , <b>2020</b> , 10, 3016	4.9	6
252	A fast method for the detection of irinotecan in plasma samples by combining solid phase extraction and differential pulse voltammetry. <i>Analytical and Bioanalytical Chemistry</i> , <b>2020</b> , 412, 1585-1595	4.4	4
251	Prognostic role of macrophage infiltration and monocyte-to-lymphocyte ratio in stage III colon cancer: The MIRROR study.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, e16118-e16118	2.2	1
250	Genetic Markers of the Host to Predict the Efficacy of Colorectal Cancer Targeted Therapy. <i>Current Medicinal Chemistry</i> , <b>2020</b> , 27, 4249-4273	4.3	10
249	A new high-performance liquid chromatography-tandem mass spectrometry method for the determination of sunitinib and N-desethyl sunitinib in human plasma: Light-induced isomerism overtaking towards therapeutic drug monitoring in clinical routine. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , <b>2020</b> , 179, 113319	3.5	5

248	A TGF- $\beta$ associated genetic score to define prognosis and platinum sensitivity in advanced epithelial ovarian cancer. <i>Gynecologic Oncology</i> , <b>2020</b> , 156, 233-242	4.9	2
247	Pharmacogenetic score predicts overall survival, progression-free survival and platinum sensitivity in ovarian cancer. <i>Pharmacogenomics</i> , <b>2020</b> , 21, 995-1010	2.6	
246	SERRS multiplexing with multivalent nanostructures for the identification and enumeration of epithelial and mesenchymal cells. <i>Scientific Reports</i> , <b>2020</b> , 10, 15805	4.9	5
245	Generating evidence for precision medicine: considerations made by the Ubiquitous Pharmacogenomics Consortium when designing and operationalizing the PREPARE study. <i>Pharmacogenetics and Genomics</i> , <b>2020</b> , 30, 131-144	1.9	10
244	Immune Checkpoint Inhibitors as Monotherapy or Within a Combinatorial Strategy in Advanced Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	7
243	CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological Conditions. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	14
242	Fluorescent Imprinted Nanoparticles for the Effective Monitoring of Irinotecan in Human Plasma. <i>Nanomaterials</i> , <b>2020</b> , 10,	5.4	2
241	Germline variability and tumor expression level of ribosomal protein gene RPL28 are associated with survival of metastatic colorectal cancer patients. <i>Scientific Reports</i> , <b>2019</b> , 9, 13008	4.9	7
240	Clonal Evolution of c.375+1G>A Mutation in Pre- and Post-Neo-Adjuvant Chemotherapy (NACT) Tumor Samples in High-Grade Serous Ovarian Cancer (HGSOC). <i>Cells</i> , <b>2019</b> , 8,	7.9	3
239	Proof-of-Concept Multistage Biomimetic Liposomal DNA Origami Nanosystem for the Remote Loading of Doxorubicin. <i>ACS Medicinal Chemistry Letters</i> , <b>2019</b> , 10, 517-521	4.3	23
238	New Challenges in Tumor Mutation Heterogeneity in Advanced Ovarian Cancer by a Targeted Next-Generation Sequencing (NGS) Approach. <i>Cells</i> , <b>2019</b> , 8,	7.9	19
237	Estimating the Effectiveness of DPYD Genotyping in Italian Individuals Suffering from Cancer Based on the Cost of Chemotherapy-Induced Toxicity. <i>American Journal of Human Genetics</i> , <b>2019</b> , 104, 1158-1168	11	17
236	Azathioprine Biotransformation in Young Patients with Inflammatory Bowel Disease: Contribution of Glutathione-S Transferase M1 and A1 Variants. <i>Genes</i> , <b>2019</b> , 10,	4.2	4
235	FARMAPRICE: A Pharmacogenetic Clinical Decision Support System for Precise and Cost-Effective Therapy. <i>Genes</i> , <b>2019</b> , 10,	4.2	5
234	rs4143815-, a New Potential Immunogenetic Biomarker of Biochemical Recurrence in Locally Advanced Prostate Cancer after Radiotherapy. <i>International Journal of Molecular Sciences</i> , <b>2019</b> , 20,	6.3	3
233	Novel immunotherapeutic approaches for hepatocellular carcinoma treatment. <i>Expert Review of Clinical Pharmacology</i> , <b>2019</b> , 12, 453-470	3.8	17
232	New Insight into Therapies Targeting Angiogenesis in Hepatocellular Carcinoma. <i>Cancers</i> , <b>2019</b> , 11,	6.6	27
231	A Pan-Cancer Approach to Predict Responsiveness to Immune Checkpoint Inhibitors by Machine Learning. <i>Cancers</i> , <b>2019</b> , 11,	6.6	16

230	Circulating-Free DNA Analysis in Hepatocellular Carcinoma: A Promising Strategy to Improve Patients Management and Therapy Outcomes. <i>International Journal of Molecular Sciences</i> , <b>2019</b> , 20,	6.3	20
229	Combination of germline variations associated with survival of folinic acid, fluorouracil and irinotecan-treated metastatic colorectal cancer patients. <i>Pharmacogenomics</i> , <b>2019</b> , 20, 1179-1187	2.6	2
228	The use of pharmacogenetics to increase the safety of colorectal cancer patients treated with fluoropyrimidines. <b>2019</b> , 2, 116-130		1
227	Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , <b>2019</b> , 25, 3870-3896	5.6	40
226	Development and validation of LC-MS/MS method for imatinib and norimatinib monitoring by finger-prick DBS in gastrointestinal stromal tumor patients. <i>PLoS ONE</i> , <b>2019</b> , 14, e0225225	3.7	9
225	An Effective Multi-Stage Liposomal DNA Origami Nanosystem for In Vivo Cancer Therapy. <i>Cancers</i> , <b>2019</b> , 11,	6.6	18
224	Germline Polymorphisms in the Nuclear Receptors PXR and VDR as Novel Prognostic Markers in Metastatic Colorectal Cancer Patients Treated With FOLFIRI. <i>Frontiers in Oncology</i> , <b>2019</b> , 9, 1312	5.3	6
223	A surface enhanced Raman scattering based colloid nanosensor for developing therapeutic drug monitoring. <i>Journal of Colloid and Interface Science</i> , <b>2019</b> , 533, 621-626	9.3	22
222	A New Genetic Risk Score to Predict the Outcome of Locally Advanced or Metastatic Breast Cancer Patients Treated With First-Line Exemestane: Results From a Prospective Study. <i>Clinical Breast Cancer</i> , <b>2019</b> , 19, 137-145.e4	3	4
221	The Genotype for DPYD Risk Variants in Patients With Colorectal Cancer and the Related Toxicity Management Costs in Clinical Practice. <i>Clinical Pharmacology and Therapeutics</i> , <b>2019</b> , 105, 994-1002	6.1	17
220	Enzyme-Based Electrochemical Biosensor for Therapeutic Drug Monitoring of Anticancer Drug Irinotecan. <i>Analytical Chemistry</i> , <b>2018</b> , 90, 6012-6019	7.8	22
219	Immunogenetics of prostate cancer: a still unexplored field of study. <i>Pharmacogenomics</i> , <b>2018</b> , 19, 263-283		2
218	Peptide biosensors for anticancer drugs: Design in silico to work in denaturing environment. <i>Biosensors and Bioelectronics</i> , <b>2018</b> , 100, 298-303	11.8	15
217	Practical fluorimetric assay for the detection of anticancer drug SN-38 in human plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , <b>2018</b> , 159, 73-81	3.5	6
216	Association of -3 rs1053004 and rs11574077 With FOLFIRI-Related Gastrointestinal Toxicity in Metastatic Colorectal Cancer Patients. <i>Frontiers in Pharmacology</i> , <b>2018</b> , 9, 367	5.6	11
215	Host genetic profiling to increase drug safety in colorectal cancer from discovery to implementation. <i>Drug Resistance Updates</i> , <b>2018</b> , 39, 18-40	23.2	16
214	Carbon Dots from Sugars and Ascorbic Acid: Role of the Precursors on Morphology, Properties, Toxicity, and Drug Uptake. <i>ACS Medicinal Chemistry Letters</i> , <b>2018</b> , 9, 832-837	4.3	56
213	Polymer-Mediated Delivery of siRNAs to Hepatocellular Carcinoma: Variables Affecting Specificity and Effectiveness. <i>Molecules</i> , <b>2018</b> , 23,	4.8	13

212	Analytical aspects of sunitinib and its geometric isomerism towards therapeutic drug monitoring in clinical routine. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , <b>2018</b> , 160, 360-367	3.5	16
211	Identification of Novel Somatic Mutations in Patients with High-Grade Serous Ovarian Cancer (HGSOc) Using Next-Generation Sequencing (NGS). <i>International Journal of Molecular Sciences</i> , <b>2018</b> , 19,	6.3	6
210	A new high-performance liquid chromatography-tandem mass spectrometry method for the determination of paclitaxel and 6-hydroxy-paclitaxel in human plasma: Development, validation and application in a clinical pharmacokinetic study. <i>PLoS ONE</i> , <b>2018</b> , 13, e0193500	3.7	6
209	Safe core-satellite magneto-plasmonic nanostructures for efficient targeting and photothermal treatment of tumor cells. <i>Nanoscale</i> , <b>2018</b> , 10, 976-984	7.7	24
208	Biosensing Technologies for Therapeutic Drug Monitoring. <i>Current Medicinal Chemistry</i> , <b>2018</b> , 25, 4354-4377	4.3	20
207	Inorganic Nanoparticles for Cancer Therapy: A Transition from Lab to Clinic. <i>Current Medicinal Chemistry</i> , <b>2018</b> , 25, 4269-4303	4.3	96
206	The Clinical Translation of Organic Nanomaterials for Cancer Therapy: A Focus on Polymeric Nanoparticles, Micelles, Liposomes and Exosomes. <i>Current Medicinal Chemistry</i> , <b>2018</b> , 25, 4224-4268	4.3	67
205	Label-Free Quantification of Anticancer Drug Imatinib in Human Plasma with Surface Enhanced Raman Spectroscopy. <i>Analytical Chemistry</i> , <b>2018</b> , 90, 12670-12677	7.8	27
204	Standard fluoropyrimidine dosages in chemoradiation therapy result in an increased risk of severe toxicity in DPYD variant allele carriers. <i>European Journal of Cancer</i> , <b>2018</b> , 104, 210-218	7.5	5
203	A Clinical-Genetic Score to Identify Surgically Resected Colorectal Cancer Patients Benefiting From an Adjuvant Fluoropyrimidine-Based Therapy. <i>Frontiers in Pharmacology</i> , <b>2018</b> , 9, 1101	5.6	4
202	Voltammetric behaviour of the anticancer drug irinotecan and its metabolites in acetonitrile. Implications for electrochemical therapeutic drug monitoring. <i>Electrochimica Acta</i> , <b>2018</b> , 289, 483-493	6.7	8
201	Mass spectrometry in the pharmacokinetic studies of anticancer natural products. <i>Mass Spectrometry Reviews</i> , <b>2017</b> , 36, 213-251	11	16
200	Cost Evaluation of Irinotecan-Related Toxicities Associated With the UGT1A1*28 Patient Genotype. <i>Clinical Pharmacology and Therapeutics</i> , <b>2017</b> , 102, 123-130	6.1	23
199	Bottom-up synthesis of carbon nanoparticles with higher doxorubicin efficacy. <i>Journal of Controlled Release</i> , <b>2017</b> , 248, 144-152	11.7	41
198	Field-assisted paper spray mass spectrometry for therapeutic drug monitoring: 1. the case of imatinib in plasma. <i>Journal of Mass Spectrometry</i> , <b>2017</b> , 52, 283-289	2.2	4
197	Strategies to optimize siRNA delivery to hepatocellular carcinoma cells. <i>Expert Opinion on Drug Delivery</i> , <b>2017</b> , 14, 797-810	8	18
196	SNCA 30TR genetic variants in patients with Parkinson disease and REM sleep behavior disorder. <i>Neurological Sciences</i> , <b>2017</b> , 38, 1233-1240	3.5	21
195	UGT1A polymorphisms as genetic biomarkers for hepatocellular carcinoma risk in Caucasian population. <i>Liver International</i> , <b>2017</b> , 37, 1345-1353	7.9	14

194	Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium. <i>Clinical Pharmacology and Therapeutics</i> , <b>2017</b> , 101, 341-358	6.1	157
193	Androgen Receptor (AR) Gene (CAG) <sub>n</sub> and (GGN) <sub>n</sub> Length Polymorphisms and Symptoms in Young Males With Long-Lasting Adverse Effects After Finasteride Use Against Androgenic Alopecia. <i>Sexual Medicine</i> , <b>2017</b> , 5, e61-e71	2.7	13
192	Hypoxic Modulation of HLA-G Expression through the Metabolic Sensor HIF-1 in Human Cancer Cells. <i>Journal of Immunology Research</i> , <b>2017</b> , 2017, 4587520	4.5	20
191	Ubiquitous Pharmacogenomics (U-PGx): The Time for Implementation is Now. An Horizon2020 Program to Drive Pharmacogenomics into Clinical Practice. <i>Current Pharmaceutical Biotechnology</i> , <b>2017</b> , 18, 204-209	2.6	22
190	HLA-G 30TR Polymorphisms Predict Drug-Induced G3-4 Toxicity Related to Folinic Acid/5-Fluorouracil/Oxaliplatin (FOLFOX4) Chemotherapy in Non-Metastatic Colorectal Cancer. <i>International Journal of Molecular Sciences</i> , <b>2017</b> , 18,	6.3	9
189	Exceptional Chemotherapy Response in Metastatic Colorectal Cancer Associated With Hyper-Indel-Hypermutated Cancer Genome and Comutation of and. <i>JCO Precision Oncology</i> , <b>2017</b> ,	3.6	1
188	Genotype-Guided Dosing Study of FOLFIRI plus Bevacizumab in Patients with Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 918-924	12.9	27
187	Nanocarriers in cancer clinical practice: a pharmacokinetic issue. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , <b>2017</b> , 13, 583-599	6	39
186	Improved Progression-Free Survival in Irinotecan-Treated Metastatic Colorectal Cancer Patients Carrying the HNF1A Coding Variant p.I27L. <i>Frontiers in Pharmacology</i> , <b>2017</b> , 8, 712	5.6	8
185	Pharmacogenomics of Targeted Agents for Personalization of Colorectal Cancer Treatment. <i>International Journal of Molecular Sciences</i> , <b>2017</b> , 18,	6.3	19
184	Impact of DNA repair gene polymorphisms on the risk of biochemical recurrence after radiotherapy and overall survival in prostate cancer. <i>Oncotarget</i> , <b>2017</b> , 8, 22863-22875	3.3	6
183	Nano albumin bound-paclitaxel in pancreatic cancer: Current evidences and future directions. <i>World Journal of Gastroenterology</i> , <b>2017</b> , 23, 5875-5886	5.6	54
182	Genetic biomarkers for hepatocellular cancer risk in a caucasian population. <i>World Journal of Gastroenterology</i> , <b>2017</b> , 23, 6674-6684	5.6	18
181	Pregnane X receptor, constitutive androstane receptor and hepatocyte nuclear factors as emerging players in cancer precision medicine. <i>Pharmacogenomics</i> , <b>2016</b> , 17, 1547-71	2.6	16
180	Exosomes increase the therapeutic index of doxorubicin in breast and ovarian cancer mouse models. <i>Nanomedicine</i> , <b>2016</b> , 11, 2431-41	5.6	137
179	Nuclear receptors and drug metabolism for the personalization of cancer therapy. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2016</b> , 12, 291-306	5.5	14
178	Enhanced Chemotherapeutic Behavior of Open-Caged DNA@Doxorubicin Nanostructures for Cancer Cells. <i>Journal of Cellular Physiology</i> , <b>2016</b> , 231, 106-10	7	26
177	Detection of low-quantity anticancer drugs by surface-enhanced Raman scattering. <i>Analytical and Bioanalytical Chemistry</i> , <b>2016</b> , 408, 2123-31	4.4	31

176	Improved Doxorubicin Encapsulation and Pharmacokinetics of Ferritin-Fusion Protein Nanocarriers Bearing Proline, Serine, and Alanine Elements. <i>Biomacromolecules</i> , <b>2016</b> , 17, 514-22	6.9	67
175	Candidate germline polymorphisms of genes belonging to the pathways of four drugs used in osteosarcoma standard chemotherapy associated with risk, survival and toxicity in non-metastatic high-grade osteosarcoma. <i>Oncotarget</i> , <b>2016</b> , 7, 61970-61987	3.3	26
174	Predictive role of microRNA-related genetic polymorphisms in the pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients. <i>Oncotarget</i> , <b>2016</b> , 7, 19781-93	3.3	11
173	Pharmacogenetics Biomarkers and Their Specific Role in Neoadjuvant Chemoradiotherapy Treatments: An Exploratory Study on Rectal Cancer Patients. <i>International Journal of Molecular Sciences</i> , <b>2016</b> , 17,	6.3	10
172	DNA Nanotechnology for Cancer Therapy. <i>Theranostics</i> , <b>2016</b> , 6, 710-25	12.1	96
171	Development and validation of a microRNA-based signature (MiROvar) to predict early relapse or progression of epithelial ovarian cancer: a cohort study. <i>Lancet Oncology</i> , <b>2016</b> , 17, 1137-1146	21.7	82
170	Field-assisted paper spray mass spectrometry for the quantitative evaluation of imatinib levels in plasma. <i>European Journal of Mass Spectrometry</i> , <b>2016</b> , 22, 217-228	1.1	3
169	Cross-validation of a mass spectrometric-based method for the therapeutic drug monitoring of irinotecan: implementation of matrix-assisted laser desorption/ionization mass spectrometry in pharmacokinetic measurements. <i>Analytical and Bioanalytical Chemistry</i> , <b>2016</b> , 408, 5369-77	4.4	7
168	Fluorescent molecularly imprinted nanogels for the detection of anticancer drugs in human plasma. <i>Biosensors and Bioelectronics</i> , <b>2016</b> , 86, 913-919	11.8	17
167	Association of the HLA-G 30TR polymorphisms with colorectal cancer in Italy: a first insight. <i>International Journal of Immunogenetics</i> , <b>2016</b> , 43, 32-9	2.3	14
166	Polysaccharides for the Delivery of Antitumor Drugs. <i>Materials</i> , <b>2015</b> , 8, 2569-2615	3.5	84
165	Clinical predictive circulating peptides in rectal cancer patients treated with neoadjuvant chemoradiotherapy. <i>Journal of Cellular Physiology</i> , <b>2015</b> , 230, 1822-8	7	13
164	Diagnostic value of plasma and urinary 2-hydroxyglutarate to identify patients with isocitrate dehydrogenase-mutated glioma. <i>Oncologist</i> , <b>2015</b> , 20, 562-7	5.7	42
163	A novel UGT1 marker associated with better tolerance against irinotecan-induced severe neutropenia in metastatic colorectal cancer patients. <i>Pharmacogenomics Journal</i> , <b>2015</b> , 15, 513-20	3.5	11
162	Exosomal doxorubicin reduces the cardiac toxicity of doxorubicin. <i>Nanomedicine</i> , <b>2015</b> , 10, 2963-2971	5.6	80
161	Biocompatible tailored zirconia mesoporous nanoparticles with high surface area for theranostic applications. <i>Journal of Materials Chemistry B</i> , <b>2015</b> , 3, 7300-7306	7.3	18
160	MTHFR-1298 A>C (rs1801131) is a predictor of survival in two cohorts of stage II/III colorectal cancer patients treated with adjuvant fluoropyrimidine chemotherapy with or without oxaliplatin. <i>Pharmacogenomics Journal</i> , <b>2015</b> , 15, 219-25	3.5	16
159	Clinical validity of a DPYD-based pharmacogenetic test to predict severe toxicity to fluoropyrimidines. <i>International Journal of Cancer</i> , <b>2015</b> , 137, 2971-80	7.5	48



158	ABCC5 and ABCG1 polymorphisms predict irinotecan-induced severe toxicity in metastatic colorectal cancer patients. <i>Pharmacogenetics and Genomics</i> , <b>2015</b> , 25, 573-83	1.9	25
157	The development of a matrix-assisted laser desorption/ionization (MALDI)-based analytical method for determination of irinotecan levels in human plasma: preliminary results. <i>Journal of Mass Spectrometry</i> , <b>2015</b> , 50, 959-62	2.2	4
156	Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: Toward targeted personalized therapy. <i>Drug Resistance Updates</i> , <b>2015</b> , 20, 39-70	23.2	56
155	Surface-enhanced Raman spectroscopy of the anti-cancer drug irinotecan in presence of human serum albumin. <i>Colloids and Surfaces B: Biointerfaces</i> , <b>2015</b> , 127, 41-6	6	37
154	Highly selective salicylketoxime-based estrogen receptor agonists display antiproliferative activities in a glioma model. <i>Journal of Medicinal Chemistry</i> , <b>2015</b> , 58, 1184-94	8.3	19
153	Development and validation of a high-performance liquid chromatography-tandem mass spectrometry method for the simultaneous determination of irinotecan and its main metabolites in human plasma and its application in a clinical pharmacokinetic study. <i>PLoS ONE</i> , <b>2015</b> , 10, e0118194	3.7	32
152	Prognostic Role of Serum Antibody Immunity to p53 Oncogenic Protein in Ovarian Cancer: A Systematic Review and a Meta-Analysis. <i>PLoS ONE</i> , <b>2015</b> , 10, e0140351	3.7	15
151	HLA-G 30TR Polymorphisms Impact the Prognosis of Stage II-III CRC Patients in Fluoropyrimidine-Based Treatment. <i>PLoS ONE</i> , <b>2015</b> , 10, e0144000	3.7	22
150	Metabolomics biomarkers of frailty in elderly breast cancer patients. <i>Journal of Cellular Physiology</i> , <b>2014</b> , 229, 898-902	7	35
149	The effect of the UGT1A1*28 allele on survival after irinotecan-based chemotherapy: a collaborative meta-analysis. <i>Pharmacogenomics Journal</i> , <b>2014</b> , 14, 424-31	3.5	30
148	How to engineer superhydrophobic micromechanical sensors preserving mass resolution. <i>Sensors and Actuators B: Chemical</i> , <b>2014</b> , 199, 62-69	8.5	4
147	Matrix-assisted laser desorption/ionization, nanostructure-assisted laser desorption/ionization and carbon nanohorns in the detection of antineoplastic drugs. 1. The cases of irinotecan, sunitinib and 6-alpha-hydroxy paclitaxel. <i>European Journal of Mass Spectrometry</i> , <b>2014</b> , 20, 445-59	1.1	6
146	A pharmacogenetic survey of androgen receptor (CAG) <sub>n</sub> and (GGN) <sub>n</sub> polymorphisms in patients experiencing long term side effects after finasteride discontinuation. <i>International Journal of Biological Markers</i> , <b>2014</b> , 29, e310-6	2.8	16
145	Genetic diversity of the KIR/HLA system and outcome of patients with metastatic colorectal cancer treated with chemotherapy. <i>PLoS ONE</i> , <b>2014</b> , 9, e84940	3.7	28
144	Identification and characterization of a new reversible MAGL inhibitor. <i>Bioorganic and Medicinal Chemistry</i> , <b>2014</b> , 22, 3285-91	3.4	36
143	Inhibition of host immune response in colorectal cancer: human leukocyte antigen-G and beyond. <i>World Journal of Gastroenterology</i> , <b>2014</b> , 20, 3778-94	5.6	12
142	Diagnostic value of plasma and urinary 2-hydroxyglutarate to identify patients with IDH-mutated glioma.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 2037-2037	2.2	
141	A UGT1A1 genotype-guided dosing study of irinotecan in metastatic colorectal cancer (mCRC) patients (pts) treated with FOLFIRI plus bevacizumab (BEV).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 562-562	2.2	22

140	Phase I trial of docetaxel, oxaliplatin, and capecitabine (DOC) in untreated gastric cancer patients. <i>International Journal of Clinical Oncology</i> , <b>2013</b> , 18, 510-6	4.2	5
139	Fluorescent carbon nanoparticles in medicine for cancer therapy. <i>ACS Medicinal Chemistry Letters</i> , <b>2013</b> , 4, 1012-3	4.3	56
138	A novel CDH1 germline missense mutation in a sporadic gastric cancer patient in north-east of Italy. <i>Clinical and Experimental Medicine</i> , <b>2013</b> , 13, 149-57	4.9	14
137	A prospective validation pharmacogenomic study in the adjuvant setting of colorectal cancer patients treated with the 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX4) regimen. <i>Pharmacogenomics Journal</i> , <b>2013</b> , 13, 403-9	3.5	57
136	Dissecting Pin1 and phospho-pRb regulation. <i>Journal of Cellular Physiology</i> , <b>2013</b> , 228, 73-7	7	15
135	Potential hazard drug-drug interaction between boosted protease inhibitors and vinblastine in HIV patients with Hodgkin's lymphoma. <i>Aids</i> , <b>2013</b> , 27, 1033-1035	3.5	13
134	Pharmacogenetics of ABC and SLC transporters in metastatic colorectal cancer patients receiving first-line FOLFIRI treatment. <i>Pharmacogenetics and Genomics</i> , <b>2013</b> , 23, 549-57	1.9	38
133	Refining the UGT1A haplotype associated with irinotecan-induced hematological toxicity in metastatic colorectal cancer patients treated with 5-fluorouracil/irinotecan-based regimens. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2013</b> , 345, 95-101	4.7	43
132	Pharmacogenetics of the nuclear hormone receptors: the missing link between environment and drug effects?. <i>Pharmacogenomics</i> , <b>2013</b> , 14, 2035-54	2.6	13
131	The prolyl isomerase Pin1 acts synergistically with CDK2 to regulate the basal activity of estrogen receptor in breast cancer. <i>PLoS ONE</i> , <b>2013</b> , 8, e55355	3.7	19
130	pRb controls estrogen receptor alpha protein stability and activity. <i>Oncotarget</i> , <b>2013</b> , 4, 875-83	3.3	15
129	miRNA pharmacogenomics: the new frontier for personalized medicine in cancer?. <i>Pharmacogenomics</i> , <b>2012</b> , 13, 1635-50	2.6	20
128	Polymorphic thymidylate synthase gene impacts on overall survival of patients with epithelial ovarian cancer after platinum-based chemotherapy. <i>Pharmacogenomics</i> , <b>2012</b> , 13, 1609-19	2.6	7
127	2-D gel electrophoresis: constructing 2D-gel proteome reference maps. <i>Methods in Molecular Biology</i> , <b>2012</b> , 815, 163-73	1.4	3
126	A Pilot Study Correlating IDH-1/2 Gene Status with 2-Hydroxyglutarate (2HG) Concentration in Plasma and Urine from Patients (PTS) with Glioma. <i>Annals of Oncology</i> , <b>2012</b> , 23, ix144	10.3	2
125	Pharmaco-metabolomics: an emerging "omics" tool for the personalization of anticancer treatments and identification of new valuable therapeutic targets. <i>Journal of Cellular Physiology</i> , <b>2012</b> , 227, 2827-31	7	56
124	Critical choices for modeling breast cancer in transgenic mouse models. <i>Journal of Cellular Physiology</i> , <b>2012</b> , 227, 2988-91	7	11
123	Androgen receptor serine 81 mediates Pin1 interaction and activity. <i>Cell Cycle</i> , <b>2012</b> , 11, 3415-20	4.7	23

122	Nucleotide excision repair gene variants and association with survival in osteosarcoma patients treated with neoadjuvant chemotherapy. <i>Pharmacogenomics Journal</i> , <b>2012</b> , 12, 476-83	3.5	52
121	Tumor response is predicted by patient genetic profile in rectal cancer patients treated with neo-adjuvant chemo-radiotherapy. <i>Pharmacogenomics Journal</i> , <b>2011</b> , 11, 214-26	3.5	54
120	High-throughput plasma docetaxel quantification by liquid chromatography-tandem mass spectrometry. <i>Clinica Chimica Acta</i> , <b>2011</b> , 412, 358-64	6.2	26
119	Research highlights. MCL1 and FBW7 as new predictive candidate biomarkers of anti-tubulin agents. <i>Pharmacogenomics</i> , <b>2011</b> , 12, 1379-80	2.6	2
118	KIR/HLA combination associated with the risk of complications in celiac disease. <i>International Journal of Biological Markers</i> , <b>2011</b> , 26, 221-8	2.8	8
117	KIR molecules: recent patents of interest for the diagnosis and treatment of several autoimmune diseases, chronic inflammation, and B-cell malignancies. <i>Recent Patents on DNA &amp; Gene Sequences</i> , <b>2011</b> , 5, 169-74		4
116	Role of genetic polymorphisms and mutations in colorectal cancer therapy (Review). <i>Molecular Medicine Reports</i> , <b>2011</b> , 4, 203-8	2.9	20
115	Genetic profiling and ovarian cancer therapy (review). <i>Molecular Medicine Reports</i> , <b>2011</b> , 4, 771-7	2.9	22
114	HLA DR-DQ combination associated with the increased risk of developing human HCV positive non-Hodgkin lymphoma is related to the type II mixed cryoglobulinemia. <i>Tissue Antigens</i> , <b>2010</b> , 75, 127-35		22
113	PPAR signaling pathway and cancer-related proteins are involved in celiac disease-associated tissue damage. <i>Molecular Medicine</i> , <b>2010</b> , 16, 199-209	6.2	36
112	Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 866-71	2.2	128
111	Irinotecan in the adjuvant treatment of colon cancer: is the story finished or does personalized therapy open new opportunities?. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, e199	2.2	4
110	Do gliadin and tissue transglutaminase mediate PPAR downregulation in intestinal cells of patients with coeliac disease?. <i>Gut</i> , <b>2010</b> , 59, 1730-1	19.2	11
109	Liquid chromatography tandem mass spectrometry assay for fast and sensitive quantification of estrone-sulfate. <i>Clinica Chimica Acta</i> , <b>2010</b> , 411, 574-80	6.2	18
108	Fast liquid chromatography-tandem mass spectrometry method for routine assessment of irinotecan metabolic phenotype. <i>Therapeutic Drug Monitoring</i> , <b>2010</b> , 32, 638-46	3.2	14
107	MTHFR polymorphisms in gastric cancer and in first-degree relatives of patients with gastric cancer. <i>Tumor Biology</i> , <b>2010</b> , 31, 23-32	2.9	25
106	Drug interactions among the epidermal growth factor receptor inhibitors, other biologics and cytotoxic agents. <i>Pharmacology &amp; Therapeutics</i> , <b>2010</b> , 128, 82-90	13.9	10
105	Galectin-10, eosinophils, and celiac disease. <i>Annals of the New York Academy of Sciences</i> , <b>2009</b> , 1173, 357-64	6.5	22

104	Characterization of antibodies directed against the immunoglobulin light kappa chain variable chain region (VK) of hepatitis C virus-related type-II mixed cryoglobulinemia and B-cell proliferations. <i>Annals of the New York Academy of Sciences</i> , <b>2009</b> , 1173, 152-60	6.5	11
103	Meta- and pooled analyses of the methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism and colorectal cancer: a HuGE-GSEC review. <i>American Journal of Epidemiology</i> , <b>2009</b> , 170, 1207-21	3.8	83
102	A liquid chromatography-tandem mass spectrometry method for the simultaneous determination of exemestane and its metabolite 17-dihydroexemestane in human plasma. <i>Journal of Mass Spectrometry</i> , <b>2009</b> , 44, 920-8	2.2	21
101	Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 2457-65	2.2	183
100	Effect of TP53 Arg72Pro and MDM2 SNP309 polymorphisms on the risk of high-grade osteosarcoma development and survival. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 3550-6	12.9	56
99	C677T and A1298C MTHFR polymorphisms, a challenge for antifolate and fluoropyrimidine-based therapy personalisation. <i>European Journal of Cancer</i> , <b>2009</b> , 45, 1333-51	7.5	91
98	Two-dimensional gel proteome reference map of human small intestine. <i>Proteome Science</i> , <b>2009</b> , 7, 10	2.6	7
97	Differential proteomic analysis of hepatocellular carcinoma <b>2009</b> , 36,		1
96	Lopinavir-ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi's sarcoma. <i>Clinical Pharmacology and Therapeutics</i> , <b>2008</b> , 83, 601-6	6.1	42
95	Recent prognostic factors in diffuse large B-cell lymphoma indicate NF-kappaB pathway as a target for new therapeutic strategies. <i>Leukemia and Lymphoma</i> , <b>2008</b> , 49, 2048-58	1.9	23
94	Pharmacogenetic relevance of MTHFR polymorphisms. <i>Pharmacogenomics</i> , <b>2008</b> , 9, 1195-206	2.6	55
93	UGT1A1*28 and other UGT1A polymorphisms as determinants of irinotecan toxicity. <i>Journal of Chemotherapy</i> , <b>2008</b> , 20, 158-65	2.3	24
92	Mixed cryoglobulinemia syndrome as an additional autoimmune disorder associated with risk for lymphoma development. <i>Blood</i> , <b>2008</b> , 111, 5760	2.2	11
91	Rapid and sensitive analysis of vincristine in human plasma using on-line extraction combined with liquid chromatography/tandem mass spectrometry. <i>Rapid Communications in Mass Spectrometry</i> , <b>2008</b> , 22, 519-25	2.2	30
90	HCV inhibits antigen processing and presentation and induces oxidative stress response in gastric mucosa. <i>Proteomics - Clinical Applications</i> , <b>2008</b> , 2, 1290-9	3.1	8
89	Pharmacogenetics in Cancer Management: Scenario for Tailored Therapy <b>2008</b> , 389-403		
88	Clinical implications of genetic polymorphisms on stomach cancer drug therapy. <i>Pharmacogenomics Journal</i> , <b>2007</b> , 7, 76-80	3.5	4
87	Pharmacogenetics and stomach cancer: an update. <i>Pharmacogenomics</i> , <b>2007</b> , 8, 497-505	2.6	14

86	Pharmacology of Epidermal Growth Factor Inhibitors. <i>International Journal of Biological Markers</i> , <b>2007</b> , 22, 24-39	2.8	9
85	Recent patents relating to HCV molecules like putative targets for therapeutic intervention. <i>Recent Patents on DNA &amp; Gene Sequences</i> , <b>2007</b> , 1, 186-94		
84	Pharmacology of epidermal growth factor inhibitors. <i>International Journal of Biological Markers</i> , <b>2007</b> , 22, 24-39	2.8	14
83	Pharmacology of epidermal growth factor inhibitors. <i>International Journal of Biological Markers</i> , <b>2007</b> , 22, S24-39	2.8	4
82	Oral etoposide in elderly patients with advanced non small cell lung cancer: a clinical and pharmacological study. <i>Journal of Chemotherapy</i> , <b>2006</b> , 18, 188-91	2.3	5
81	Innovative schedule of oral idarubicin in elderly patients with metastatic breast cancer: comprehensive results of a phase II multi-institutional study with pharmacokinetic drug monitoring. <i>Annals of Oncology</i> , <b>2006</b> , 17, 807-12	10.3	19
80	Reply to the Letter to the Editor from Chowbay et al. <i>Clinical Cancer Research</i> , <b>2006</b> , 12, 1942.2-1942	12.9	
79	MTHFR and ALL risk: a challenge. <i>Leukemia and Lymphoma</i> , <b>2006</b> , 47, 1203-4	1.9	4
78	Is tailored therapy feasible in oncology?. <i>Critical Reviews in Oncology/Hematology</i> , <b>2006</b> , 57, 79-101	7	16
77	The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, 3061-8	2.2	280
76	Prevalence of methylenetetrahydrofolate reductase polymorphisms in young patients with inflammatory bowel disease. <i>Digestive Diseases and Sciences</i> , <b>2006</b> , 51, 474-9	4	14
75	Sarcomas and pharmacogenetics. <i>Pharmacogenomics</i> , <b>2005</b> , 6, 585-601	2.6	4
74	Tailored therapy of colorectal cancer: results, challenges and future directions. <i>Cancer Journal (Sudbury, Mass)</i> , <b>2005</b> , 11, 175-88	2.2	3
73	Carboxylesterase isoform 2 mRNA expression in peripheral blood mononuclear cells is a predictive marker of the irinotecan to SN38 activation step in colorectal cancer patients. <i>Clinical Cancer Research</i> , <b>2005</b> , 11, 6901-7	12.9	32
72	Potential hazard of pharmacokinetic interactions between lopinavir/ritonavir protease inhibitors and irinotecan. <i>Aids</i> , <b>2005</b> , 19, 2043-2044	3.5	15
71	Lack of association of CYP1 B1*3 polymorphism and ovarian cancer in a Caucasian population. <i>International Journal of Biological Markers</i> , <b>2004</b> , 19, 160-3	2.8	19
70	Effect of highly active antiretroviral therapy (HAART) on pharmacokinetics and pharmacodynamics of doxorubicin in patients with HIV-associated non-Hodgkin's lymphoma. <i>Annals of Oncology</i> , <b>2004</b> , 15, 1805-9	10.3	28
69	Pharmacogenomics and stomach cancer. <i>Pharmacogenomics</i> , <b>2004</b> , 5, 627-41	2.6	6

68	Thymidylate synthetase mRNA levels are increased in liver metastases of colorectal cancer patients resistant to fluoropyrimidine-based chemotherapy. <i>BMC Cancer</i> , <b>2004</b> , 4, 11	4.8	22
67	New oral drugs in older patients: a review of idarubicin in elderly patients. <i>Critical Reviews in Oncology/Hematology</i> , <b>2004</b> , 49, 153-63	7	25
66	Pharmacokinetic optimisation of treatment with oral etoposide. <i>Clinical Pharmacokinetics</i> , <b>2004</b> , 43, 441-66	6.6	59
65	Pharmacokinetic comparison of 120-hour infusion versus hyperfractionated oral administration of idarubicin. <i>Journal of Chemotherapy</i> , <b>2004</b> , 16, 193-200	2.3	1
64	Uridine diphosphoglucuronosyl transferase and methylenetetrahydrofolate reductase polymorphisms as genomic predictors of toxicity and response to irinotecan-, antifolate- and fluoropyrimidine-based chemotherapy. <i>Journal of Chemotherapy</i> , <b>2004</b> , 16 Suppl 4, 31-5	2.3	11
63	High throughput screening of genetic polymorphisms by matrix-assisted laser desorption ionization time-of-flight mass spectrometry. <i>Combinatorial Chemistry and High Throughput Screening</i> , <b>2004</b> , 7, 707-25	1.3	12
62	UGT1A1*28 polymorphism in ovarian cancer patients. <i>Oncology Reports</i> , <b>2004</b> , 12, 457-62	3.5	19
61	. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2003</b> , 26, e73-e79	2.7	2
60	Radiosensitivity in multidrug-resistant and cisplatin-resistant human carcinoma cell lines. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2003</b> , 26, e73-9	2.7	3
59	Methylenetetrahydrofolate Reductase Genotype in Diffuse Large B-Cell Lymphomas with and without Hypermethylation of the DNA Repair Gene O6-Methylguanine DNA Methyltransferase. <i>International Journal of Biological Markers</i> , <b>2003</b> , 18, 218-221	2.8	11
58	Effect of methylenetetrahydrofolate reductase 677C-->T polymorphism on toxicity and homocysteine plasma level after chronic methotrexate treatment of ovarian cancer patients. <i>International Journal of Cancer</i> , <b>2003</b> , 103, 294-9	7.5	107
57	Pharmacogenetics of irinotecan. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , <b>2003</b> , 3, 225-37		27
56	Methylenetetrahydrofolate reductase genotype in diffuse large B-cell lymphomas with and without hypermethylation of the DNA repair gene O6-methylguanine DNA methyltransferase. <i>International Journal of Biological Markers</i> , <b>2003</b> , 18, 218-21	2.8	16
55	Methylenetetrahydrofolate reductase 677 C-->T polymorphism and risk of proximal colon cancer in north Italy. <i>Clinical Cancer Research</i> , <b>2003</b> , 9, 743-8	12.9	48
54	Pharmacogenetics of stomach cancer. <i>I Supplementi Di Tumori</i> , <b>2003</b> , 2, S19-22		1
53	Idarubicin. <i>Tumori</i> , <b>2002</b> , 88, S73-S74	1.7	2
52	Carboplatin and topotecan combination and myelosuppression. <i>Journal of Clinical Oncology</i> , <b>2002</b> , 20, 3558	2.2	4
51	Carboplatin in Elderly Patients. <i>Tumori</i> , <b>2002</b> , 88, S35-S36	1.7	

50	Population pharmacokinetics and pharmacodynamics of oral etoposide. <i>British Journal of Clinical Pharmacology</i> , <b>2001</b> , 52, 511-9	3.8	39
49	Topoisomerase I inhibitors combination chemotherapy in non-small cell lung cancer. <i>Lung Cancer</i> , <b>2001</b> , 34 Suppl 4, S37-46	5.9	42
48	MTHFR gene polymorphism and severe toxicity during adjuvant treatment of early breast cancer with cyclophosphamide, methotrexate, and fluorouracil (CMF). <i>Annals of Oncology</i> , <b>2000</b> , 11, 373-4	10.3	67
47	Resistance to methotrexate in SKOV-3 cell lines after chronic exposure to carbamazepine is associated with a decreased expression of folate receptor. <i>International Journal of Cancer</i> , <b>2000</b> , 85, 683-90	7.5	8
46	Dose-finding and pharmacologic study of chronic oral idarubicin therapy in metastatic breast cancer patients. <i>Clinical Cancer Research</i> , <b>2000</b> , 6, 2279-87	12.9	21
45	Interactions of antineoplastic chemotherapy with zidovudine pharmacokinetics in patients with HIV-related neoplasms. <i>Chemotherapy</i> , <b>1999</b> , 45, 418-28	3.2	5
44	Pharmacokinetics of oral etoposide in patients with hepatocellular carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , <b>1999</b> , 43, 287-94	3.5	38
43	Effect of cyclosporin A on protein binding of teniposide in cancer patients. <i>Anti-Cancer Drugs</i> , <b>1999</b> , 10, 511-8	2.4	7
42	Pharmacokinetic interaction between etoposide and tamoxifen in patients with hepatocellular carcinoma. <i>Anti-Cancer Drugs</i> , <b>1999</b> , 10, 815-9	2.4	5
41	Pharmacokinetic and pharmacodynamic effects of high-dose continuous intravenous verapamil infusion: clinical experience in the intensive care unit. <i>Critical Care Medicine</i> , <b>1999</b> , 27, 332-9	1.4	28
40	Radiation treatment of glottic squamous cell carcinoma, stage I and II: analysis of factors affecting prognosis. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>1998</b> , 40, 541-8	4	32
39	Role of folate receptor and reduced folate carrier in the transport of 5-methyltetrahydrofolic acid in human ovarian carcinoma cells. <i>International Journal of Cancer</i> , <b>1998</b> , 75, 125-33	7.5	53
38	Expression of folate binding protein as a prognostic factor for response to platinum-containing chemotherapy and survival in human ovarian cancer. <i>International Journal of Cancer</i> , <b>1998</b> , 79, 121-6	7.5	117
37	Homocysteine accumulation in human ovarian carcinoma ascitic/cystic fluids possibly caused by metabolic alteration of the methionine cycle in ovarian carcinoma cells. <i>European Journal of Cancer</i> , <b>1997</b> , 33, 1284-90	7.5	22
36	Cyclosporin A as a multidrug-resistant modulator in patients with renal cell carcinoma treated with teniposide. <i>British Journal of Cancer</i> , <b>1997</b> , 75, 715-21	8.7	12
35	Non-linear pharmacokinetics of high-dose intravenous verapamil. <i>British Journal of Clinical Pharmacology</i> , <b>1997</b> , 44, 255-60	3.8	8
34	Overexpression of folate binding protein in ovarian cancers. <i>International Journal of Cancer</i> , <b>1997</b> , 74, 193-8	7.5	400
33	Reversal activity of cyclosporin A and its metabolites M1, M17 and M21 in multidrug-resistant cells. <i>International Journal of Cancer</i> , <b>1997</b> , 71, 900-6	7.5	9

32	Inhibition of Pgp activity and cell cycle-dependent chemosensitivity to doxorubicin in the multidrug-resistant LoVo human colon cancer cell line. <i>European Journal of Cancer</i> , <b>1996</b> , 32A, 1591-7	7.5	15
31	Cellular pharmacology of idarubicinol in multidrug-resistant LoVo cell lines. <i>International Journal of Cancer</i> , <b>1996</b> , 67, 129-37	7.5	13
30	Determination of unbound etoposide concentration in ultrafiltered plasma by high-performance liquid chromatography with fluorimetric detection. <i>Biomedical Applications</i> , <b>1996</b> , 686, 35-41		26
29	Pharmacokinetics of doxorubicin co-administered with high-dose verapamil. <i>British Journal of Cancer</i> , <b>1995</b> , 71, 134-6	8.7	4
28	DNA flow cytometric evaluation of cell cycle distribution in ulcerative colitis: a proposed method for assessing severity of disease. <i>Gut</i> , <b>1995</b> , 36, 50-4	19.2	6
27	Structure-activity relationship of verapamil analogs and reversal of multidrug resistance. <i>Biochemical Pharmacology</i> , <b>1995</b> , 50, 1245-55	6	63
26	Effect of cyclosporine on teniposide pharmacokinetics and pharmacodynamics in patients with renal cell cancer. <i>Anti-Cancer Drugs</i> , <b>1995</b> , 6, 479-82	2.4	
25	Brief report: prognostic importance of cellular DNA content in T1-2 N0 laryngeal squamous cell carcinomas treated with radiotherapy. <i>Laryngoscope</i> , <b>1995</b> , 105, 649-52	3.6	18
24	P53 overexpression in human soft tissue sarcomas: relation to biological aggressiveness. <i>Annals of Oncology</i> , <b>1994</b> , 5, 167-72	10.3	13
23	Comparison of mechanisms responsible for resistance to idarubicin and daunorubicin in multidrug resistant LoVo cell lines. <i>Biochemical Pharmacology</i> , <b>1994</b> , 48, 1871-81	6	29
22	Functional activity of P-glycoprotein localized in subcellular structures and reversal of multidrug resistance (MDR) <b>1994</b> , 726-729		
21	p53 expression in human soft tissue sarcomas. Correlation with biological aggressiveness <b>1994</b> , 794-797		
20	Increased chemosensitivity to doxorubicin of intrinsically multidrug-resistant human colon carcinoma cells by prolonged exposure to verapamil. <i>European Journal of Cancer</i> , <b>1993</b> , 29A, 1776-8	7.5	7
19	Effect of short- and long-term treatment with omeprazole on cell cycle distribution in the gastric mucosa. Results of a flow cytometric study. <i>Scandinavian Journal of Gastroenterology</i> , <b>1993</b> , 28, 617-21	2.4	2
18	Doxorubicin, vincristine, and actinomycin-D, but not teniposide, require long-lasting uninterrupted verapamil pressure to overcome drug resistance in multidrug-resistant cells. <i>Cancer Detection and Prevention</i> , <b>1993</b> , 17, 425-32		1
17	Expression of glutathione-S-transferase-pi in human tumours. <i>European Journal of Cancer</i> , <b>1992</b> , 28A, 1441-6	7.5	35
16	Mechanism of multidrug resistance in human tumour cell lines and complete reversion of cellular resistance. <i>European Journal of Cancer</i> , <b>1992</b> , 28A, 1099-105	7.5	27
15	P-Glycoprotein but not Topoisomerase II and Glutathione-S-Transferase-Pi Accounts for Enhanced Intracellular Drug-Resistance in LoVo MDR Human Cell Lines. <i>Tumori</i> , <b>1992</b> , 78, 159-166	1.7	4



14	Expression of MDR1 and GST-pi in human soft tissue sarcomas: relation to drug resistance and biological aggressiveness. <i>Annals of Oncology</i> , <b>1992</b> , 3, 63-9	10.3	43
13	Expression of the <i>mdr1</i> gene in human colorectal carcinomas: relationship with multidrug resistance inferred from analysis of human colorectal carcinoma cell lines. <i>Cancer Chemotherapy and Pharmacology</i> , <b>1992</b> , 29, 283-9	3.5	16
12	Pleiotropic-resistant phenotype is a multifactorial phenomenon in human colon carcinoma cell lines. <i>British Journal of Cancer</i> , <b>1991</b> , 63, 51-6	8.7	46
11	Frequent Occurrence of Ha-ras Allelic Deletion in Human Ovarian Adenocarcinomas. <i>Tumori</i> , <b>1991</b> , 77, 16-20	1.7	2
10	c-myc overexpression is a tumor-specific phenomenon in a subset of human colorectal carcinomas. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>1990</b> , 116, 288-94	4.9	16
9	A pharmacological rationale for neoadjuvant chemotherapy with adriamycin in locally advanced breast cancer. <i>Anticancer Research</i> , <b>1990</b> , 10, 193-6	2.3	3
8	Sensitivity Pattern of Normal and Ha-Ras Transformed Nih3T3 Fibroblasts to Antineoplastic Drugs. <i>Tumori</i> , <b>1989</b> , 75, 423-428	1.7	13
7	Combination Antibiotic Treatment of Chemotherapy-Induced Neutropenia in Non-Leukemic Patients. <i>Tumori</i> , <b>1989</b> , 75, 443-448	1.7	
6	Effect of hyperthermia on intracellular drug accumulation and chemosensitivity in drug-sensitive and drug-resistant P388 leukaemia cell lines. <i>International Journal of Hyperthermia</i> , <b>1989</b> , 5, 163-72	3.7	33
5	In K562 leukemia cells treated with doxorubicin and hemin, a decrease in c-myc mRNA expression correlates with loss of self-renewal capability but not with erythroid differentiation. <i>Leukemia Research</i> , <b>1989</b> , 13, 279-87	2.7	13
4	Early DNA damage induced in cells exposed to N10-propargyl 5,8-dideazafolic acid (CB 3717) or methotrexate. <i>Biochemical Pharmacology</i> , <b>1988</b> , 37, 1875-6	6	2
3	Changes in Chemosensitivity of K 562 Leukemia Cells after Induction of Erythroid Differentiation by Hemin. <i>Tumori</i> , <b>1988</b> , 74, 11-17	1.7	1
2	Accumulation of DNA strand breaks in cells exposed to methotrexate or N10-propargyl-5,8-dideazafolic acid. <i>Cancer Research</i> , <b>1988</b> , 48, 2036-41	10.1	62
1	UGT1A1*28 polymorphism in ovarian cancer patients. <i>Oncology Reports</i> ,	3.5	5